Listen

News

Upsher-Smith Launches Tosymra (sumatriptan) Nasal Spray for the Acute Treatment of Migraine in Adults

Oct. 08. 2019

Maple Grove, MN - Oct 2, 2019 - Upsher-Smith Laboratories, LLC (“Upsher-Smith”, President and CEO: Rusty Field), a subsidiary of Sawai Pharmaceutical Co., Ltd. (“Sawai”, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the launch of Tosymra™ (sumatriptan) Nasal Spray, 10 mg for the acute treatment of migraine with or without aura in adults. Tosymra is a fast-acting, easy-to-use acute migraine treatment option that delivers the efficacy of an injectable in a convenient nasal spray.

Tosymra™, which was approved by the U.S. Food and Drug Administration in early 2019, was recently acquired by Upsher-Smith from Dr. Reddy’s Laboratories Limited in a strategic effort to expand and diversify the Company’s migraine portfolio.

“We’re excited to launch Tosymra™, the third product in Upsher-Smith’s growing migraine portfolio, which includes Qudexy® XR and Zembrace® SymTouch®,” said Rusty Field, President and CEO, Upsher-Smith. “Many patients face challenges during migraine attacks that make available acute treatment options inadequate. Tosymra™ Nasal Spray offers an alternative to patients whose symptoms interfere with taking oral medication or who may be dissatisfied with their current treatment regimen.”

More than 36 million patients suffer from migraines and surveys have shown that a majority are willing to try other acute treatment options.1 Patients currently using oral treatment options may face challenges including nausea and gastroparesis or vomiting which may delay or limit oral medication absorption.

1. Bigal M, Rapoport A, Aurora S, Sheftell F, Tepper S, Dahlof C., Satisfaction with Current Migraine Therapy: Experience From 2 Centers in US and Sweden. Headache. 2007 Apr; 47(4):475-9. https://doi.org/10.1111/j.1526-4610.2007.00752.x

About Intravail®

Intravail® is a registered trademark of Neurelis, Inc. Intravail® drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide drugs (up to 30,000 daltons in size) that can currently only be administered by injection. Intravail® can be utilized via the oral, buccal, dermal, and intranasal routes of drug administration.

About Upsher-Smith

Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply.

As Upsher-Smith celebrates its 100-year anniversary, the company enters a new ambitious era that has been accelerated by its 2017 acquisition by Sawai. Upsher-Smith and Sawai plan to leverage each other for growth worldwide and embark on an exciting new chapter as they seek to deliver the best value for their stakeholders, and most importantly, Do More Good™ for the patients they serve. For more information, visit https://www.upsher-smith.com.

Qudexy, Zembrace SymTouch, Tosymra and Do More Good are trademarks of Upsher-Smith Laboratories, LLC.